KBC Group NV Has $206.74 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

KBC Group NV lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,845,085 shares of the biopharmaceutical company's stock after selling 216,483 shares during the quarter. Gilead Sciences accounts for about 0.6% of KBC Group NV's portfolio, making the stock its 25th biggest holding. KBC Group NV owned 0.15% of Gilead Sciences worth $206,742,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at approximately $29,000. Sovran Advisors LLC raised its stake in Gilead Sciences by 23.0% in the 1st quarter. Sovran Advisors LLC now owns 6,838 shares of the biopharmaceutical company's stock valued at $715,000 after purchasing an additional 1,278 shares during the last quarter. Capital Advisors Wealth Management LLC lifted its holdings in Gilead Sciences by 10.4% in the 1st quarter. Capital Advisors Wealth Management LLC now owns 3,162 shares of the biopharmaceutical company's stock valued at $354,000 after purchasing an additional 298 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Gilead Sciences by 1.9% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,091,193 shares of the biopharmaceutical company's stock worth $346,368,000 after purchasing an additional 57,133 shares during the last quarter. Finally, Golden State Wealth Management LLC boosted its stake in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Up 0.2%

Shares of GILD traded up $0.20 during trading on Monday, reaching $110.87. The company's stock had a trading volume of 6,600,026 shares, compared to its average volume of 7,677,827. The company has a market cap of $137.91 billion, a price-to-earnings ratio of 23.34, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The company has a fifty day moving average of $106.39 and a two-hundred day moving average of $103.42. Gilead Sciences, Inc. has a twelve month low of $66.01 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. The business's revenue was down .3% compared to the same quarter last year. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.85%. Gilead Sciences's payout ratio is currently 66.53%.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer owned 620,268 shares in the company, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $275,425.00. Following the transaction, the chief financial officer owned 165,110 shares of the company's stock, valued at $18,190,168.70. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,500 shares of company stock valued at $5,236,245 over the last quarter. Insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of several recent analyst reports. Oppenheimer cut their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Wells Fargo & Company increased their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.